Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Gemcitabine + LOAd703|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 11||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|LOAd703||delolimogene mupadenorepvec||LOAd703 is an adenovirus engineered to express trimerized human CD40L and full-length 4-1BBL, resulting in activation of CD40L and 4-1BBL signaling, and potentially leading to reduced tumor cell viability and decreased tumor growth (PMID: 28536305).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||pancreatic cancer||not applicable||Gemcitabine + LOAd703||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Gemzar (gemcitabine) and LOAd703 combination therapy reduced cell viability in pancreatic cancer lines in culture and led to decreased tumor growth in a pancreatic cancer cell line xenograft model (PMID: 28536305).||28536305|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|